Alterity Therapeutics Limited (ATHE) Discusses Phase II Data and Development Strategy for ATH434 in Multiple System Atrophy - Slideshow (NASDAQ:ATHE) 2026-05-02
Alterity Therapeutics Limited (ATHE) Discusses Phase II Data and Development Strategy for ATH434 in Multiple System Atrophy Transcript
Акции Alterity Therapeutics растут после представления положительных данных испытания MSA на конференции
Why Levi Strauss Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket - Albemarle (NYSE:ALB), Above Food Ingredients (NASDAQ:ABVE)